用于路易体痴呆的生物流体中的生物标志物。
Biomarkers in biological fluids for dementia with Lewy bodies.
作者信息
Schade Sebastian, Mollenhauer Brit
机构信息
Paracelsus-Elena-Klinik, Klinikstraße 16, Kassel, D-34128, Germany ; Department of Clinical Neurophysiology, University Medical Center, Georg-August University, Robert-Koch Straße 40, Göttingen, 37075, Germany.
Paracelsus-Elena-Klinik, Klinikstraße 16, Kassel, D-34128, Germany ; Department of Neurosurgery, University Medical Center, Georg-August University, Robert-Koch Straße 40, Göttingen, 37075, Germany ; Department of Neuropathology, University Medical Center, Georg-August University, Robert-Koch Straße 40, Göttingen, 37075, Germany.
出版信息
Alzheimers Res Ther. 2014 Oct 16;6(5-8):72. doi: 10.1186/s13195-014-0072-3. eCollection 2014.
Dementia with Lewy bodies (DLB) has become the second most common neurodegenerative dementia due to demographic ageing. Differential diagnosis is still troublesome especially in early stages of the disease, since there is a great clinical and neuropathological overlap primarily with Alzheimer's disease and Parkinson's disease. Therefore, more specific biomarkers, not only for scientific reasons but also for clinical therapeutic decision-making, are urgently needed. In this review, we summarize the knowledge on fluid biomarkers for DLB, derived predominantly from cerebrospinal fluid. We discuss the value of well-defined markers (β-amyloid, (phosphorylated) tau, α-synuclein) as well as some promising 'upcoming' substances, which still have to be further evaluated.
由于人口老龄化，路易体痴呆（DLB）已成为第二常见的神经退行性痴呆。鉴别诊断仍然很棘手，尤其是在疾病的早期阶段，因为主要与阿尔茨海默病和帕金森病在临床和神经病理学上存在很大重叠。因此，迫切需要更特异的生物标志物，这不仅出于科学原因，也为了临床治疗决策。在本综述中，我们总结了主要来自脑脊液的DLB体液生物标志物的相关知识。我们讨论了明确标志物（β-淀粉样蛋白、（磷酸化）tau蛋白、α-突触核蛋白）的价值以及一些仍需进一步评估的有前景的“新兴”物质。
Zotero 插件